Callan Capital LLC Makes New $375,000 Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Callan Capital LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 4,629 shares of the biopharmaceutical company’s stock, valued at approximately $375,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Strategic Blueprint LLC raised its position in shares of Gilead Sciences by 8.1% during the third quarter. Strategic Blueprint LLC now owns 4,388 shares of the biopharmaceutical company’s stock worth $329,000 after purchasing an additional 328 shares during the period. Proficio Capital Partners LLC acquired a new position in Gilead Sciences during the 3rd quarter valued at about $207,000. Koshinski Asset Management Inc. increased its holdings in Gilead Sciences by 5.1% during the 3rd quarter. Koshinski Asset Management Inc. now owns 2,975 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 145 shares in the last quarter. Harrington Investments INC lifted its holdings in shares of Gilead Sciences by 2.2% in the third quarter. Harrington Investments INC now owns 20,786 shares of the biopharmaceutical company’s stock valued at $1,558,000 after purchasing an additional 450 shares in the last quarter. Finally, Verity & Verity LLC raised its position in Gilead Sciences by 0.8% in the 3rd quarter. Verity & Verity LLC now owns 333,109 shares of the biopharmaceutical company’s stock valued at $26,539,000 after buying an additional 2,708 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the sale, the insider now directly owns 100,936 shares in the company, valued at approximately $7,386,496.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by company insiders.

Gilead Sciences Price Performance

Shares of GILD stock traded up $0.15 on Friday, hitting $65.42. 12,349,126 shares of the stock traded hands, compared to its average volume of 7,477,028. The firm has a market cap of $81.45 billion, a price-to-earnings ratio of 14.54, a PEG ratio of 1.20 and a beta of 0.19. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The firm has a 50 day simple moving average of $71.28 and a two-hundred day simple moving average of $76.25. Gilead Sciences, Inc. has a 52 week low of $64.63 and a 52 week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. During the same period in the previous year, the business earned $1.37 earnings per share. The business’s revenue was up 5.3% on a year-over-year basis. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 4.2 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were given a dividend of $0.77 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.71%. Gilead Sciences’s dividend payout ratio (DPR) is presently 68.44%.

Analysts Set New Price Targets

GILD has been the topic of a number of recent analyst reports. Barclays dropped their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Monday, February 12th. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a report on Wednesday. UBS Group decreased their target price on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Morgan Stanley cut their price target on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a report on Friday. Finally, Wells Fargo & Company decreased their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. Eleven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $83.87.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.